Pár Alajos
Pécsi Tudományegyetem, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika Pécs.
Orv Hetil. 2009 Jan 4;150(1):19-26. doi: 10.1556/OH.2009.28529.
As hepatitis B and C virus (HBV, HCV) play a pivotal role in the development of hepatocellular carcinoma (HCC), the prophylaxis and treatment of these infections may mean also the prevention of HCC. The primary prevention of HCC is vaccination against HBV as well as the screening of blood donors for HBV and HCV markers. The means of secondary HCC prevention are as follows: antiviral therapy of HBV and HCV-related hepatitis and cirrhosis, screening ("surveillance") of cirrhotic patients for HCC using alpha-fetoprotein and ultrasound, and adjuvant antiviral treatment of HCC patients following curative tumor resection/ablation. It may be anticipated that the world-wide spread of HBV vaccination, the more effective individual treatment and novel antivirals will lead to the decrease of HCC incidence in the not so distant future.
由于乙型肝炎病毒和丙型肝炎病毒（HBV、HCV）在肝细胞癌（HCC）的发生发展中起关键作用，对这些感染的预防和治疗可能也意味着预防HCC。HCC的一级预防是接种乙肝疫苗以及对献血者进行HBV和HCV标志物筛查。HCC二级预防的方法如下：对HBV和HCV相关肝炎及肝硬化进行抗病毒治疗，使用甲胎蛋白和超声对肝硬化患者进行HCC筛查（“监测”），以及对接受根治性肿瘤切除/消融后的HCC患者进行辅助抗病毒治疗。可以预期，乙肝疫苗在全球的普及、更有效的个体化治疗以及新型抗病毒药物将在不久的将来导致HCC发病率下降。
